Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.
3.

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.

Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT.

J Intern Med. 2004 Jul;256(1):1-14. Review.

4.
5.

A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus.

Chilcott J, Tappenden P, Jones ML, Wight JP.

Clin Ther. 2001 Nov;23(11):1792-823; discussion 1791. Review.

PMID:
11768834
6.

Effects of pioglitazone on lipid and lipoprotein metabolism.

Betteridge DJ.

Diabetes Obes Metab. 2007 Sep;9(5):640-7. Review.

PMID:
17697057
7.

The role of pioglitazone in modifying the atherogenic lipoprotein profile.

Hanefeld M.

Diabetes Obes Metab. 2009 Aug;11(8):742-56. doi: 10.1111/j.1463-1326.2009.01048.x. Epub 2009 Jun 10. Review.

PMID:
19519869
8.

The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.

Dai X, Wang H, Jing Z, Fu P.

Curr Med Res Opin. 2014 Sep;30(9):1777-86. doi: 10.1185/03007995.2014.921608. Epub 2014 May 28. Review.

PMID:
24805140
9.

Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.

Monami M, Vitale V, Ambrosio ML, Bartoli N, Toffanello G, Ragghianti B, Monami F, Marchionni N, Mannucci E.

Adv Ther. 2012 Sep;29(9):736-46. doi: 10.1007/s12325-012-0045-5. Epub 2012 Aug 24. Review.

PMID:
22923161
10.

Pharmacokinetics and clinical efficacy of pioglitazone.

Hanefeld M.

Int J Clin Pract Suppl. 2001 Sep;(121):19-25. Review.

PMID:
11594240
11.

Oral hypoglycaemic agent failure.

Banerjee S, Sinharoy K, Singh AK.

J Indian Med Assoc. 2002 Jul;100(7):452-6. Review.

PMID:
12674170
12.

Actos (pioglitazone): a new treatment for type 2 diabetes.

Lawrence JM, Reckless JP.

Hosp Med. 2001 Jul;62(7):411-6. Review.

PMID:
11480129
13.

PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.

Erdmann E, Dormandy J, Wilcox R, Massi-Benedetti M, Charbonnel B.

Vasc Health Risk Manag. 2007;3(4):355-70. Review.

14.

The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?

Rizzo M, Christ ER, Rini GB, Spinas GA, Berneis K.

Expert Opin Pharmacother. 2008 Sep;9(13):2295-303. doi: 10.1517/14656566.9.13.2295 . Review.

PMID:
18710354
15.

Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.

Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL.

Ann Intern Med. 2007 Sep 18;147(6):386-99. Epub 2007 Jul 16. Review. Erratum in: Ann Intern Med. 2007 Dec 18;147(12):887.

PMID:
17638715
16.

[Metformin, lipids and atherosclerosis].

Joffroy-Lavieuville M, Triadou N, Noel M.

Journ Annu Diabetol Hotel Dieu. 1984:361-6. Review. French. No abstract available.

PMID:
6399538
17.

[Clinical aspects of the problem of hyperlipoproteinemia and age].

Reuter W.

Z Gesamte Inn Med. 1981 Mar;36(5):141-5. Review. German.

PMID:
7018098
18.

Vascular benefits of gliclazide beyond glycemic control.

Jennings PE.

Metabolism. 2000 Oct;49(10 Suppl 2):17-20. Review.

PMID:
11078471
19.

Atherogenic lipoproteins and diabetes mellitus.

Yoshino G, Hirano T, Kazumi T.

J Diabetes Complications. 2002 Jan-Feb;16(1):29-34. Review.

PMID:
11872363
20.

Clinical relevance of the oxidative stress concept.

Haffner SM.

Metabolism. 2000 Feb;49(2 Suppl 1):30-4. Review.

PMID:
10693918

Supplemental Content

Support Center